IMARC Research, a CRO offering monitoring, auditing and training services and ImageIQ, an imaging contract research organization (CRO) and, have announced a partnership that will strengthen the abilities of both organization’s clients to manage the complexities of imaging within clinical trials, and to enhance FDA approvals by ensuring that scientific data is optimized and that processes are compliant. ImageIQ will provide IMARC clients with their imaging and image analysis clinical trial expertise. Conversely, IMARC will bring its 14 years of clinical trial management experience to ImageIQ clients that utilize ImageIQ’s imaging analytics and software development expertise.
“Medical imaging technology and imaging analytics have changed vastly in the past few years, providing whole new strata of clinical trial data,” said Sandra Maddock, CEO and President of IMARC Research. “However, with the addition of various imaging modalities into a clinical trial comes increased complexities and risks that need to be considered and carefully monitored in order to ensure accurate, complete, and evaluable data at the end of the study.” This partnership differentiates IMARC Research as a CRO that can accommodate those added complexities with various risk mitigation approaches including clinical trial monitoring, auditing, and Good Clinical Practice (GCP) training. “We are very excited to enter into this partnership with ImageIQ to bring this level of expertise to our client base,” said Maddock.
“Our clients often begin working with us on innovative ways to utilize imaging within clinical trials, to improve data quality, to quantify product marketing claims, and to strengthen FDA documentation. As a part of that process, they quickly realize that imaging enhances the scientific results that they garner. It is also clear to them that adding imaging requires a sophisticated process to ensure imaging compliance monitoring and auditing process. Our clients are already very pleased that IMARC Research can provide that expertise.”
Photo Credit: SalFalko